Three-dimensional quantitative structure-activity relationship (3D-QSAR) models were developed for 100 anilinoquinazolines, inhibiting epidermal growth factor receptor (EGFR) kinase. The studies included molecular field analysis (MFA) and receptor surface analysis (RSA). The cross-validated r2 (r2cv) values are 0.81 and 0.79 for MFA and RSA, respectively. The predictive ability of these models was validated by 28 test set molecules. The results of the best QSAR model were further compared with structure-based investigations using docking studies with the crystal structure of EGFR kinase domain. The results helped to understand the nature of substituents at the 6- and 7-positions, thereby providing new guidelines for the design of novel inhibitors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0968-0896(03)00482-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design, synthesis and antitumour activity of pyrimidine derivatives as novel selective EGFR kinase inhibitors.
Mol Divers
January 2025
School of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong, People's Republic of China.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, often linked to overexpression or abnormal activation of the epidermal growth factor receptor (EGFR). The issue of developing resistance to third-generation EGFR kinase inhibitors, such as osimertinib, underscores the urgent need for new therapies to overcome this resistance. Our findings revealed that compound A8 exhibits 88.
View Article and Find Full Text PDFCianidanol from Sea Buckthorn Exert Anti-Inflammatory Effects by the Inhibiting JAK2/STAT3 Signaling Pathway via an Integrative Pharmacology Strategy.
Plant Foods Hum Nutr
January 2025
Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Sea buckthorn is a model of medicine and food homology, but the chemical composition and mechanism of anti-inflammatory effects are limited. In this study, the key components and mechanisms of the anti-inflammatory effects of sea buckthorn were identified based on UPLC-Q-TOF-MS, network pharmacology, molecular docking, molecular dynamics and RAW264.7 cells.
View Article and Find Full Text PDFCircular RNA promoted tumorigenesis and osimertinib resistance in lung adenocarcinoma via a circular RNA-microRNA network.
J Thorac Dis
December 2024
Department of Urology, Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Background: Tyrosine kinase inhibitors (TKIs) are the first-line therapy for patients with non-small cell lung cancer (NSCLC) with sensitized mutations in the epidermal growth factor receptor (). However, resistance to TKIs is a major clinical issue that affects the survival and prognosis of the patients, with the mechanisms underlying this resistance remaining elusive. Circular RNAs (circRNAs) are a class of single-stranded, covalently closed RNA molecules, which are generated from pre-messenger RNAs (mRNAs) through back splicing.
View Article and Find Full Text PDFThe evolving landscape of adjuvant therapy in T1-T2N0 resected non-small cell lung cancer: a narrative review.
J Thorac Dis
December 2024
Department of Surgery, Yale University School of Medicine, Yale University, New Haven, CT, USA.
Background And Objective: Lung cancer recurrence after complete surgical resection of early-stage T1-T2N0 non-small cell lung cancer (NSCLC) remains a problem due to unrecognized micrometastatic disease. The objective of this review is to present and summarize data from major randomized trials in which have studied the survival benefit of adjuvant therapy for early-stage NSCLC.
Methods: Information used to write this paper was collected from PubMed and the National Clinical Trial registry from the National Library of Medicine.
Osimertinib as a neoadjuvant therapy in resectable EGFR-mutant non-small cell lung cancer: a real-world, multicenter retrospective study.
Transl Lung Cancer Res
December 2024
Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China (UESTC), Chengdu, China.
Background: Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), has been authorized for use in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). This study aimed to evaluate the effectiveness and safety of neoadjuvant osimertinib in individuals with resectable locally advanced NSCLC harboring EGFR mutation.
Methods: Ten centers located in mainland China took part in a single-arm, real-world, multicenter retrospective study (registration number: ChiCTR2100049954).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!